Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raymond Rawson

Neurological Surgery Petoskey, MI Medical Doctor

NPI 1164457008 CMS profile 324839

2390 Mitchell Park Dr Ste B, Petoskey, MI 49770

Open in the dashboard

General payments

$83,073

104 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raymond Rawson of Petoskey, MI is reported in the CMS Open Payments database as having received $83,073 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,625 7
2024 General $26,741 16
2023 General $16,944 18
2022 General $10,460 18
2021 General $5,377 26
2020 General $221 5
2019 General $2,705 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raymond Rawson
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Raymond Rawson were reported at $20,625. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Raymond Rawson Neurological Surgery median Middle half National median
2019 $2,705 $582 $138–$3,006 $163
2020 $221 $294 $76–$2,174 $114
2021 $5,377 $387 $105–$2,432 $132
2022 $10,460 $542 $139–$2,989 $149
2023 $16,944 $534 $145–$2,697 $160
2024 $26,741 $574 $155–$3,046 $164
2025 $20,625 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Innovasis Inc $74,247 34 payments
  2. Boston Scientific Corporation $8,029 51 payments
  3. Spine Wave, Inc. $349 5 payments
  4. Abbott Laboratories $195 9 payments
  5. Spineology Inc. $120 1 payment
  6. Nevro Corp. $105 2 payments
  7. Djo, LLC $16 1 payment
  8. Stryker Corporation $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,556 10 payments
  2. Travel and Lodging $17,335 24 payments
  3. Consulting Fee $4,460 2 payments
  4. Food and Beverage $3,722 68 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $2,363 7 payments
  2. General - Therapies $2,073 6 payments
  3. WAVEWRITER ALPHA $1,544 9 payments
  4. General - Pain Management $423 5 payments
  5. GENERAL PAIN MANAGEMENT $353 6 payments
  6. WaveWriter Alpha Prime 16 $166 6 payments
  7. OPTIMESH EXPANDABLE INTERBODY FUSION SYSTEM $120 1 payment
  8. Superion Indirect Decompression System $112 1 payment
  9. Senza $105 2 payments
  10. Proclaim IPG $104 4 payments
  11. Other $453 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

344

Median for Neurosurgery: 83

Drug cost

$2,050

Median for Neurosurgery: $872

Branded share of claims

64.8%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 163 $959
Oxycodone Hcl Generic 52 $287
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 37 $231
Gabapentin Generic 23 $213
Morphine Sulfate Er Morphine Sulfate Brand 23 $164
Hydromorphone Hcl Generic 14 $69
Tizanidine Hcl Generic 16 $65
Dexamethasone Generic 16 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$78,577

Medicare's payments for the services billed

Medicare patients

93

Average age 72

Services billed

355

59 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Depression 33%
Ischemic heart disease 23%
COPD 23%
Chronic kidney disease 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record